GILD - Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership.
Their goal is to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
Assembly Bio will receive $100 million, consisting of an $84.8 million upfront payment and a $15.2 million equity investment from Gilead.
In addition, Gilead has agreed to purchase up to 29.9% of Assembly Bio's outstanding voting stock at a premium.
Gilead ...